Obsidian Therapeutics Inc.
OBXNASDAQHealthcareBiotechnology
Previous close
$19.90
−$0.29 · -1.44%
Aug 21, 4:00 PM ET
OBX company overview
Regular session · ET · Market data may be delayed.
Company profile
Company websiteA clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Madan Jagasia
- Listed since
- Aug 4, 2026
- Employees
- 3
Market position
Day range
Current $19.90
$18.44$21.33
52-week range
Current $19.90
$14.57$49.97
- Open
- $20.47
- Previous close
- $20.19
- Volume
- 1.45M
- 13.28× average
- Average volume
- 109.1K
- Average daily volume
- Market cap
- 20.7M USD
- Beta
- 2.64
- Market reference 1
- 50-day average
- $22.3725
- -11.05% below average
- 200-day average
- $22.3725
- -11.05% below average
Earnings
- EPS beat rate
- 50%
- 2 beats, 2 misses, 0 met estimates
- Average EPS surprise
- -11.40%
- 4 comparable reports
- Latest EPS result
- -14
- Estimate 165.45 · Miss by 108.46%
EPS: actual versus estimate
Recent quarterly results
ActualEstimate
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$42.00
111.06% upsidePast 12 months12-month forecastHigh $42.00Average $42.00Low $42.00
OBX news
OBX peers
ETFs holding OBX
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research OBXresearch.disclaimer